Departement of Medicine 1, Hospital Santa Maria, Lisbon, Portugal.
Clin Rev Allergy Immunol. 2010 Apr;38(2-3):307-18. doi: 10.1007/s12016-009-8162-x.
Systemic lupus erythematosus (SLE) is a disease of unknown cause that may involve one or many organ or systems. Skin involvement is a major feature in this disease, and a wide variety of skin conditions may be present. Lupus erythematosus panniculitis (LEP) constitutes a rare form of cutaneous lupus characterized by recurrent nodular or plaque lesions that can vary from a benign and mild course to a more disfiguring disease. Initial therapy includes corticosteroids, antimalarials, and azathioprine and, in refractory cases, two antimalarials in association, mycophenolate mofetil, or other immunomodulators. Intravenous immuglobulin (IVIG) is used in many autoimmune disorders, like in SLE, although clinical trials have not yet taken place. In this report, we review skin manifestations of SLE and their treatment, IVIG, and finally a case of LEP successfully treated with IVIG when other therapy modalities failed.
系统性红斑狼疮(SLE)是一种病因不明的疾病,可能涉及一个或多个器官或系统。皮肤受累是本病的一个主要特征,可能存在多种皮肤状况。狼疮性脂膜炎(LEP)构成了一种罕见的皮肤狼疮形式,其特征是反复出现结节或斑块病变,从良性和轻度病程到更具毁容性疾病不等。初始治疗包括皮质类固醇、抗疟药和硫唑嘌呤,在难治性病例中,联合使用两种抗疟药、霉酚酸酯或其他免疫调节剂。静脉注射免疫球蛋白(IVIG)用于许多自身免疫性疾病,如 SLE,尽管尚未进行临床试验。在本报告中,我们回顾了 SLE 的皮肤表现及其治疗、IVIG,最后是一例 LEP 病例,在其他治疗方法失败时成功地使用 IVIG 治疗。